# **UNITED STATES**

SECURITIES A	ND EXCHANGE CO	<b>DMMISSION</b>
	Washington, D.C. 20549	
	FORM 8-K	
	CURRENT REPORT	
Pursuant to Section 13	3 or 15(d) of the Securities Exch	ange Act of 1934
Date of Report	t (Date of earliest event reported) May	4, 2004
	In Pharmaceutica	
Delaware (State or other jurisdiction	000-26727 (Commission File Number)	68-0397820 (IRS Employer
of incorporation)		Identification No.)
371 Bel Marin Keys Boulevard, Suite		
210, Novato, California (Address of principal executive offices)		94949 (Zip Code)

Registrant s telephone number, including area code (415) 506-6700

### Not Applicable

(Former name or former address, if changed since last report)

#### Item 7. Financial Statements and Exhibits.

(a) Financial Statements of Business Acquired.

(b) Pro Forma Financial Information.

Not Applicable.

Not Applicable.

(c) Exhibits.

Exhibit 99.1 Press Release of BioMarin Pharmaceutical Inc. (the Company ) dated May 4, 2004.

#### Item 12. Results of Operations and Financial Condition.

On May 4, 2004, the Company announced financial results for its first quarter ended March 31, 2004. The Company s press release issued on May 4, 2004 is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BioMarin Pharmaceutical Inc., a Delaware corporation
(Registrant)

/s/ Louis Drapeau

Louis Drapeau

Chief Financial Officer

### EXHIBIT INDEX

Exhibit No.	Description
Exhibit 99.1	Press Release of the Registrant dated May 4, 2004